Editorial Resistance patterns to anti-PD-1 therapy in metastatic melanoma Alpaslan Ozgun, Vernon K. Sondak, Joseph Markowitz Abstract Anti-PD-1 antibodies block the immune checkpoint programmed death 1 receptor to increase T cell specific anti-tumor responses (1,2).
